Skip to Content

We invite you to try out our new beta eCFR site at We’ve made big changes to make the eCFR easier to use. Be sure to leave feedback using the 'Feedback' button on the bottom right of each page!


Guidance for Industry on Irritable Bowel Syndrome-Clinical Evaluation of Drugs for Treatment; Availability; Correction

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.


Notice; correction.


The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of May 31, 2012 (77 FR 32124). The document announced the availability of a guidance for industry entitled “Irritable Bowel Syndrome—Clinical Evaluation of Drugs for Treatment.” The document was published with an incorrect docket number. This document corrects that error.


Joyce Strong, Office of Policy and Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3208, Silver Spring, MD 20993-0002, 301-796-9148.


In FR Doc. 2012-13143, appearing on page 32124 in the Federal Register of Thursday, May 31, 2012, the following correction is made:

1. On page 32124, in the first column, in the headings section of the document, “[Docket No. FDA-2012-D-0146]” is corrected to read “[Docket No. FDA-2010-D-0146]”.

Dated: June 8, 2012.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2012-14485 Filed 6-13-12; 8:45 am]